The place of 57Co-bleomycin in the evaluation of tumours.
162 patients were investigated by 57Co-bleomycin scintigraphy. 62 of these patients were also studied with 67Ga. 142 were suspected for malignant neoplastic disease, 20 for a focal inflammatory process. Good visualization with 57Co-bleomycin was obtained in 75% of malignant tumours and in 66% with 67Ga. Most of the patients were studied for abdominal disease and in this region 57Co-bleomycin was found to be qualitatively superior to 67Ga. The principal advantage of 57Co-bleomycin is a very low tissue background specially concerning the bowel. Neither 57Co-bleomycin nor 67Ga are tumour-specific. Both radiopharmaceuticals are taken up by inflammatory processes. This is a disadvantage in tumour diagnostics but the radionuclides can be useful for localizing inflammatory foci. The possibilities of studying the localisation of radionuclides at the cellular level will be discussed.
D000818:Animals; D001761:Bleomycin / Q000031:analogs & derivatives; D002277:Carcinoma / Q000000981:diagnostic imaging; D005260:Female; D006801:Humans; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009369:Neoplasms / Q000000981:diagnostic imaging*; D009374:Neoplasms, Experimental / Q000000981:diagnostic imaging; D011877:Radionuclide Imaging; D012008:Recurrence; D002583:Uterine Cervical Neoplasms / Q000000981:diagnostic imaging
C030187:cobalt bleomycin; D001761:Bleomycin